簡體 | 繁體
loading...
海外博客
    • 首頁
    • 新聞
    • 讀圖
    • 財經
    • 教育
    • 家居
    • 健康
    • 美食
    • 時尚
    • 旅遊
    • 影視
    • 博客
    • 群吧
    • 論壇
    • 電台
  • 熱點
  • 原創
  • 時政
  • 旅遊
  • 美食
  • 家居
  • 健康
  • 財經
  • 教育
  • 情感
  • 星座
  • 時尚
  • 娛樂
  • 曆史
  • 文化
  • 社區
  • 幫助
您的位置: 文學城 » 博客 »為什麽胰島素在美國怎麽貴

為什麽胰島素在美國怎麽貴

2019-03-15 14:08:22

萬發

萬發
吃喝玩樂奔諾獎
首頁 文章頁 文章列表 博文目錄
給我悄悄話
打印 被閱讀次數
 
1923年,胰島素是發明者把胰島素的專利僅僅賣了1美元,就是為了需要它的人能夠低價得到它。現在一小瓶就要300美元,爾在1996 年隻有25美元,價格漲了百分之一千。
很多患者,傾家蕩產,就是為了用胰島素治療自己的糖尿病。

The human cost of insulin in America

 

This is the list of what Laura Marston has sacrificed to keep herself alive: Her car, her furniture, her apartment, her retirement fund, her dog.

At 36 years old, she has already sold all of her possessions twice to afford the insulin her body needs every day.

Insulin is not like other drugs. It's a natural hormone that controls our blood sugar levels - too high causes vision loss, confusion, nausea, and eventually, organ failure; too low leads to heart irregularities, mood swings, seizures, loss of consciousness.

For most of us, our bodies produce insulin naturally. But for Type 1 (T1) diabetics like Ms Marston, insulin comes in clear glass vials, handed over the pharmacy counter each month - if they can afford it.

One vial of the insulin Ms Marston uses now costs $275 (£210) without health insurance.

In 1923, the discoverers of insulin sold its patent for $1, hoping the low price would keep the essential treatment available to everyone who needed it.

Now, retail prices in the US are around the $300 range for all insulins from the three major brands that control the market.

Even accounting for inflation, that's a price increase of over 1,000%.

Stories of Americans rationing insulin - and dying for it - have been making national headlines.

The most famous case, perhaps, was 26-year-old Alec Smith, who died in 2017 less than a month after he aged out of his mother's health insurance plan. Despite working full-time making more than minimum wage, he could not afford to buy new insurance or pay the $1,000 a month for insulin without it.

 Alec Smith's mother holds a vial of her son's ashes during a protest against the high price of insulin outside Sanofi's offices in Massachusetts

Ms Marston knows the feeling - like most of the diabetics I spoke to, she has experienced frightening lapses in coverage through no fault of her own.

A few years ago, when the small law firm Ms Marston worked for abruptly closed, she found herself without an income and suddenly uninsured.

"I was spending $2,880 a month just to keep myself alive - that was more than I was making even working 50 hours a week," says Ms Marston.

She was forced to leave her home in Richmond, Virginia, to find a new job in Washington DC to ensure she could pay for insulin.

"I sold everything, including my car, and had to give up my dog - he was eight and I had to give him away - and move to DC."

There are any number of reasons why someone might still be uninsured in America - if they don't qualify for employer-sponsored insurance or lose their job like Ms Marston had, for example, or if they cannot afford to pay for a plan on their own.

 "I'm not sure I'll ever get over the pain of having to choose my life over our life together," Ms Marston says of her dog, Nicky

Ms Marston was diagnosed with T1 diabetes when she was 14. She laughs when recalling how the price of insulin in 1996 - $25 for one vial - was a shock to her.

Two decades later, Ms Marston still uses the same formula of insulin - Eli Lilly's Humalog. Even the packaging is the same.

"Nothing about it has changed, except the price has gone up from $21 a vial to $275 a vial."

It's the same story for Sanofi's Apidra and Novo Nordisk's Novolog.

So who's to blame?

Most patients point the finger at the pharmaceutical companies, who in turn bring up problems with government regulations and insurance providers.

At the heart of the issue is the complex mystery around who pays what for insulin in the US.

There are five terms essential to this discussion - list price, net price, rebates, co-payments and deductibles.

  • List price is set by a pharmaceutical company, and in many cases is what uninsured diabetics pay
  • Net price is the actual profit the company receives for a drug
  • Rebates are discounts on drugs negotiated for insurance companies
  • Co-payments are what an insured person pays for a prescription, out-of-pocket
  • Deductibles, which can be as high as $10,000, are what insurance policies say must be paid before the insurer picks up the rest

Insurance companies enlist third-party negotiators, called pharmacy benefit managers, to fix discounts with drug manufacturers that in turn result in smaller co-payment prices for their users. Experts say part of the system's problem is a lack of transparency around how these rebates are negotiated and how much actually makes its way to patients.

This system also means that insurers end up with different rates for each drug company, so a brand of insulin that has a minimal co-pay under one insurance could cost the full list price under another.

Ms Marston has been tracking insulin list prices for years. By her calculations, for insulin alone, she'll need close to $7m to live until she's 70 if she pays out of pocket.

"It's led to a situation where I decided I couldn't have kids because I don't feel financially stable enough," Ms Marston says.

But drug manufacturers argue that very few people ever face paying list price.

Eli Lilly said in a statement to the BBC that 95% of people using Humalog in the US pay under $100 a month for their prescription, and that of the 600,000 using Humalog, "about 1,600 people without insurance have not utilised the [assistance] benefits we offer".

Novo Nordisk and Sanofi detailed similar patient assistance programmes in their statements. And several diabetics I spoke to did say that these programmes helped them- if they qualified.

But another advocate, Kristen Daniels, says she was faced with a $2,400 price tag for one month of insulin and because she was technically insured, she couldn't get assistance.

"I called my insurance, I called the manufacturer, and no one could help me because I hadn't reached my deductible," Ms Daniels says.

Pharmaceutical companies have also emphasised that rising list prices did not result in commensurate profits. Eli Lilly's spokesman says their net price has actually gone down in the last five years; Sanofi's said their insulin profits are 25% lower in 2019 than 2012.

According to a report by the American Diabetes Association (ADA) and the University of Southern California Center for Health Policy and Economics, between 2007 and 2016, major brand insulin list prices have increased by 252%, while net prices saw less growth at 57%.

And there are cheaper options in the US for some: WalMart insulin, for example, is a re-branded version of a Novo Nordisk formula which retails for around $25 per vial in most states. But the formula is older, less effective, and some, like Ms Marston, are allergic to it.

This is another key issue in the debate around skyrocketing insulin prices. Each formula works differently for each individual. It takes many T1 patients years to feel comfortable managing their dosing with a particular brand.

Several diabetics I spoke to say they have been forced to switch insulins by their insurance plans - even against the recommendation of their physicians - if they wanted to avoid paying the list price for their preferred brand.

The ADA says this "non-medical switching" is more than an inconvenience - it's potentially dangerous, requiring constant monitoring on the patient's part and consultations with a physician.

Serious or permanent complications like blindness or kidney disease can arise if a diabetic is put through too many extreme sugar highs and lows.

In America, where insurance coverage goes hand-in-hand with employment and options are limited, many T1 diabetics make sacrifices in other parts of their lives to keep affording insulin - whether that's staying with a stressful job or switching insulin formulas at the behest of an insurer.

The expression that comes up again and again in the US T1 community is: "We're hostages".

BBC

登錄後才可評論.
  • 文學城簡介
  • 廣告服務
  • 聯係我們
  • 招聘信息
  • 注冊筆名
  • 申請版主
  • 收藏文學城

WENXUECITY.COM does not represent or guarantee the truthfulness, accuracy, or reliability of any of communications posted by other users.

Copyright ©1998-2025 wenxuecity.com All rights reserved. Privacy Statement & Terms of Use & User Privacy Protection Policy

今日熱點

  • 魔灘買房記:當房地產經紀人悄悄給自己發獎金魔灘買房
  • 寧可少交10個朋友,也不多樹1個敵人雅酷原創
  • 即將分崩離析的美國(1.6)caizane
  • 為石平太郎說幾句閑話fubin
  • 舉報是製止暴力保護自由的必要手段蔣公子
  • 地中海跳島遊 - 從巴勒莫到撒丁島風語空靈
  • 柯克之死、進化論與保守派的教育危機feiteng
  • 蘋果vs穀歌lionhill
  • 祝福溫哥華EuphoriaF
  • 試析 毛、周晚年的一件公案——毛澤東4條指示背後的玄機(上)江天雲月
  • 緩慢地度過人生塵凡無憂
  • 在美和公司博弈專利產權的職場十年經曆:1. 始於孟浪伽子羅衿
  • 家有紈絝貓北美新疆妞
  • 海外職場有這種事情麽?修忍術!明了的土垚

一周熱點

  • 我隱約地看到了未來戰爭的模樣songling
  • 簡單的人,做簡單的事喝白開水健康
  • 維生素 D 的那些事burpeejump
  • 英雄無悔 戰神末路 Kirk之死BeijingGirl1
  • 方便麵漲價了帕格尼尼
  • 博士後的財務自由之路A-mao
  • 德國並沒有對中國電車敞開大門, 或者不得不敞開大門京男
  • 半夜鬧鬼,我撥打了911GoBucks!
  • 宗教信仰30畝地
  • 人人持槍,真的可以不亂嗎?行者無疆1970
  • 一婚、(二婚與昏昏)毛驢縣令
  • 預製菜招你惹你了?mychina
  • 健康家常美食,Trader Joe’s的好東西,周末大爬梯菲兒天地
  • 多麽痛的領悟,祖國是一種錯覺麥姐
為什麽胰島素在美國怎麽貴
切換到網頁版
萬發

萬發 名博

為什麽胰島素在美國怎麽貴

萬發 (2019-03-15 14:08:22) 評論 (0)
 
1923年,胰島素是發明者把胰島素的專利僅僅賣了1美元,就是為了需要它的人能夠低價得到它。現在一小瓶就要300美元,爾在1996 年隻有25美元,價格漲了百分之一千。
很多患者,傾家蕩產,就是為了用胰島素治療自己的糖尿病。

The human cost of insulin in America

 

This is the list of what Laura Marston has sacrificed to keep herself alive: Her car, her furniture, her apartment, her retirement fund, her dog.

At 36 years old, she has already sold all of her possessions twice to afford the insulin her body needs every day.

Insulin is not like other drugs. It's a natural hormone that controls our blood sugar levels - too high causes vision loss, confusion, nausea, and eventually, organ failure; too low leads to heart irregularities, mood swings, seizures, loss of consciousness.

For most of us, our bodies produce insulin naturally. But for Type 1 (T1) diabetics like Ms Marston, insulin comes in clear glass vials, handed over the pharmacy counter each month - if they can afford it.

One vial of the insulin Ms Marston uses now costs $275 (£210) without health insurance.

In 1923, the discoverers of insulin sold its patent for $1, hoping the low price would keep the essential treatment available to everyone who needed it.

Now, retail prices in the US are around the $300 range for all insulins from the three major brands that control the market.

Even accounting for inflation, that's a price increase of over 1,000%.

Stories of Americans rationing insulin - and dying for it - have been making national headlines.

The most famous case, perhaps, was 26-year-old Alec Smith, who died in 2017 less than a month after he aged out of his mother's health insurance plan. Despite working full-time making more than minimum wage, he could not afford to buy new insurance or pay the $1,000 a month for insulin without it.

 Alec Smith's mother holds a vial of her son's ashes during a protest against the high price of insulin outside Sanofi's offices in Massachusetts

Ms Marston knows the feeling - like most of the diabetics I spoke to, she has experienced frightening lapses in coverage through no fault of her own.

A few years ago, when the small law firm Ms Marston worked for abruptly closed, she found herself without an income and suddenly uninsured.

"I was spending $2,880 a month just to keep myself alive - that was more than I was making even working 50 hours a week," says Ms Marston.

She was forced to leave her home in Richmond, Virginia, to find a new job in Washington DC to ensure she could pay for insulin.

"I sold everything, including my car, and had to give up my dog - he was eight and I had to give him away - and move to DC."

There are any number of reasons why someone might still be uninsured in America - if they don't qualify for employer-sponsored insurance or lose their job like Ms Marston had, for example, or if they cannot afford to pay for a plan on their own.

 "I'm not sure I'll ever get over the pain of having to choose my life over our life together," Ms Marston says of her dog, Nicky

Ms Marston was diagnosed with T1 diabetes when she was 14. She laughs when recalling how the price of insulin in 1996 - $25 for one vial - was a shock to her.

Two decades later, Ms Marston still uses the same formula of insulin - Eli Lilly's Humalog. Even the packaging is the same.

"Nothing about it has changed, except the price has gone up from $21 a vial to $275 a vial."

It's the same story for Sanofi's Apidra and Novo Nordisk's Novolog.

So who's to blame?

Most patients point the finger at the pharmaceutical companies, who in turn bring up problems with government regulations and insurance providers.

At the heart of the issue is the complex mystery around who pays what for insulin in the US.

There are five terms essential to this discussion - list price, net price, rebates, co-payments and deductibles.

  • List price is set by a pharmaceutical company, and in many cases is what uninsured diabetics pay
  • Net price is the actual profit the company receives for a drug
  • Rebates are discounts on drugs negotiated for insurance companies
  • Co-payments are what an insured person pays for a prescription, out-of-pocket
  • Deductibles, which can be as high as $10,000, are what insurance policies say must be paid before the insurer picks up the rest

Insurance companies enlist third-party negotiators, called pharmacy benefit managers, to fix discounts with drug manufacturers that in turn result in smaller co-payment prices for their users. Experts say part of the system's problem is a lack of transparency around how these rebates are negotiated and how much actually makes its way to patients.

This system also means that insurers end up with different rates for each drug company, so a brand of insulin that has a minimal co-pay under one insurance could cost the full list price under another.

Ms Marston has been tracking insulin list prices for years. By her calculations, for insulin alone, she'll need close to $7m to live until she's 70 if she pays out of pocket.

"It's led to a situation where I decided I couldn't have kids because I don't feel financially stable enough," Ms Marston says.

But drug manufacturers argue that very few people ever face paying list price.

Eli Lilly said in a statement to the BBC that 95% of people using Humalog in the US pay under $100 a month for their prescription, and that of the 600,000 using Humalog, "about 1,600 people without insurance have not utilised the [assistance] benefits we offer".

Novo Nordisk and Sanofi detailed similar patient assistance programmes in their statements. And several diabetics I spoke to did say that these programmes helped them- if they qualified.

But another advocate, Kristen Daniels, says she was faced with a $2,400 price tag for one month of insulin and because she was technically insured, she couldn't get assistance.

"I called my insurance, I called the manufacturer, and no one could help me because I hadn't reached my deductible," Ms Daniels says.

Pharmaceutical companies have also emphasised that rising list prices did not result in commensurate profits. Eli Lilly's spokesman says their net price has actually gone down in the last five years; Sanofi's said their insulin profits are 25% lower in 2019 than 2012.

According to a report by the American Diabetes Association (ADA) and the University of Southern California Center for Health Policy and Economics, between 2007 and 2016, major brand insulin list prices have increased by 252%, while net prices saw less growth at 57%.

And there are cheaper options in the US for some: WalMart insulin, for example, is a re-branded version of a Novo Nordisk formula which retails for around $25 per vial in most states. But the formula is older, less effective, and some, like Ms Marston, are allergic to it.

This is another key issue in the debate around skyrocketing insulin prices. Each formula works differently for each individual. It takes many T1 patients years to feel comfortable managing their dosing with a particular brand.

Several diabetics I spoke to say they have been forced to switch insulins by their insurance plans - even against the recommendation of their physicians - if they wanted to avoid paying the list price for their preferred brand.

The ADA says this "non-medical switching" is more than an inconvenience - it's potentially dangerous, requiring constant monitoring on the patient's part and consultations with a physician.

Serious or permanent complications like blindness or kidney disease can arise if a diabetic is put through too many extreme sugar highs and lows.

In America, where insurance coverage goes hand-in-hand with employment and options are limited, many T1 diabetics make sacrifices in other parts of their lives to keep affording insulin - whether that's staying with a stressful job or switching insulin formulas at the behest of an insurer.

The expression that comes up again and again in the US T1 community is: "We're hostages".

BBC